MICHELLE MATHY

Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

The Medicaid & CHIP Access Prescription Digital Therapeutics Act (S. 5238); Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

The Medicaid & CHIP Access Prescription Digital Therapeutics Act (S. 5238); Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

The Medicaid & CHIP Access Prescription Digital Therapeutics Act (S. 5238); Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

The Medicaid & CHIP Access Prescription Digital Therapeutics Act (S. 5238); Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

HR 7666, Restoring Hope for Mental Health & Well Being Act of 2022; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 2938, Bipartisan Safer Communities Act; S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.

The Medicaid & CHIP Access Prescription Digital Therapeutics Act (S. 5238); Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.

H.R. 5376 Reconciliation Build Back Better Act

HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); and issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, mental health, and PTSD.

DRAFT: Prescription Digital Therapeutics Legislation, H.R. 5376 Reconciliation Build Back Better Act, S. 2327 Seniors Prescription Drug Relief Act, ISSUE: Agitation in Alzheimers Disease, ISSUE: Mental Health, ISSUE: Part D Redesign impact on Low Income Subsidy beneficiaries,

H.R. 5376 Reconciliation Build Back Better Act, S. 2327 Seniors Prescription Drug Relief Act, ISSUE: Agitation in Alzheimers Disease, ISSUE: Chronic Kidney Disease and Early Detection, ISSUE: Mental Health, ISSUE: PTSD

HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); and issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, mental health, and PTSD.

HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); and issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, mental health, and PTSD.

Draft Prescription Digital Therapeutics legislation; S.2327 Seniors Prescription Drug Relief Act; and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries,

DRAFT: Prescription Digital Therapeutics Legislation, H.R. 5376 Reconciliation Build Back Better Act, S. 2327 Seniors Prescription Drug Relief Act, ISSUE: Agitation in Alzheimers Disease, ISSUE: Mental Health, ISSUE: Part D Redesign impact on Low Income Subsidy beneficiaries,

H.R. 5376 Reconciliation Build Back Better Act, S. 2327 Seniors Prescription Drug Relief Act, ISSUE: Agitation in Alzheimers Disease, ISSUE: Chronic Kidney Disease and Early Detection, ISSUE: Mental Health, ISSUE: PTSD

HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Reconciliation Build Back Better Act (provisions related to pharmaceuticals); and issues relating to diversity in clinical trials, agitation in alzheimers disease, chronic kidney disease and early detection, mental health, and PTSD.